Biotechnology

Biotechnology·Health·Market·News·Pharmaceuticals

Achieve Life Sciences Poised for Breakthrough with Cytisinicline in Battle Against Nicotine Dependence

Achieve Life Sciences Inc. aims to transform nicotine addiction therapy with its innovative treatment, Cytisinicline, and plans to submit a New Drug Application (NDA) soon. The company has seen a significant increase in cash reserves, rising from $15.6 million in 2023 to

12. March 2025

Biotechnology·Investment·Market·News·Pharmaceuticals

Arrowhead Pharmaceuticals Faces Setback as RNA Therapeutic Data Raises Investor Eyebrows

Arrowhead Pharmaceuticals faces challenges with their RNA interference drug, ARO-C3, for complement-mediated renal diseases. The drug achieved a significant 89% reduction in C3 levels, indicating potential transformative effects and the possibility of less frequent dosing. Market response was negative, with Arrowhead’s stock

10. March 2025

Biotechnology·Finance·Investing·Market·News·Opinion·S&P 500·Trading

Why Exelixis’s Bold $500M Stock Buyback Has Investors Buzzing

Exelixis shares defied a market downturn, rising 5% as the S&P 500 declined. The share jump was spurred by the announcement of a $500 million stock buyback program. This initiative reflects a strategic move to enhance shareholder value through equity buybacks. Exelixis

22. February 2025

Biotechnology·Business Strategy·Market·News·Stock Market

Why Exelixis Shares Are Skyrocketing: A Story of Triumph and Strategy

Exelixis, Inc. has approved a substantial $500 million stock repurchase plan to be completed by the end of 2025, demonstrating strong shareholder commitment. The company surpassed analyst expectations with impressive fourth-quarter earnings and robust revenue, reinforcing its financial strength and growth trajectory.

21. February 2025